Welcome to our dedicated page for APOLLOMICS SEC filings (Ticker: APLM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Apollomics Inc. (APLM) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures as a foreign private issuer listed on The Nasdaq Stock Market. Apollomics files reports on Form 20-F and Form 6-K under the Securities Exchange Act of 1934, detailing its clinical-stage oncology business, financial condition, governance changes and material events.
Through these filings, investors can review annual reports on Form 20-F for comprehensive information on Apollomics’ oncology pipeline, including vebreltinib (APL-101) and other disclosed programs, risk factors, financial statements and notes, as well as descriptions of collaborations and licensing arrangements. Interim Form 6-K reports furnish updates on topics such as PIPE financings, reverse share split implementation, auditor changes, Nasdaq listing status, operational continuity plans, and settlements of matters like the Cayman Litigation involving minority investors.
Filings also describe Apollomics’ clinical and strategic decisions, including the conclusion of the uproleselan program after an unfavorable Phase 3 bridging trial in China, termination of the APL-122 development and license agreement with Edison Oncology Holding Corporation, and the company’s focus on advancing vebreltinib through global Phase 2 trials. Disclosures on internal control over financial reporting, changes in independent registered public accounting firms, and remediation of previously identified material weaknesses are available in the same record.
On Stock Titan, Apollomics filings are updated as they are posted to EDGAR, and AI-powered summaries help explain the key points in complex documents. Users can quickly see what each 6-K or 20-F covers, from financial results and impairment charges to listing determinations and settlement agreements, without reading the full text immediately. For those researching APLM, this page is a central resource for understanding how Apollomics presents its oncology strategy, financial performance and corporate governance to regulators and investors.
Apollomics Inc. executive Yi-Kuei (Alex) Chen has reported beneficial ownership of approximately 5.3% of the company’s Class A ordinary shares. The position totals 115,171 shares when including 100 shares held directly, 101,248 shares held through Maxpro Investment Co., Ltd., 3,823 shares issuable from warrants held by Maxpro, and 10,000 restricted stock units granted as compensation.
The filing states that 5,000 RSUs vested on February 17, 2026, with another 5,000 scheduled to vest on May 17, 2026, and that this vesting pushed Chen’s beneficial ownership above the 5% threshold. Chen indicates the shares are held for investment purposes and may be increased or reduced over time, while continuing to act in his role as Chief Operating Officer and director.
Apollomics Inc. received additional funding support from its chairman and CEO, Hung‑Wen (Howard) Chen, who, together with his wholly owned entity King Regent Management Limited, beneficially owns 901,362 Class A ordinary shares, representing 41.8% of the class.
On March 30, 2026, the company issued a $2,000,000 Convertible Promissory Note to Mr. Chen as an unsecured bridge loan. The principal will automatically convert into Apollomics equity in the next equity financing that raises at least $10,000,000, at a conversion price equal to 80% of the lowest per‑share purchase price in that financing. If no such financing occurs by the eighteen‑month maturity, Mr. Chen may elect to convert the note into Class A ordinary shares based on the average closing price over the ten trading days before maturity.
Mr. Chen holds 138,334 Class A ordinary shares directly, and King Regent holds 763,028 shares. In addition, on March 15, 2026, 5,000 restricted stock units granted to Mr. Chen vested, each representing the right to receive one Class A ordinary share.
Apollomics Inc. entered into a $2,000,000 unsecured Convertible Promissory Note with its Chairman and CEO, Hung-Wen (Howard) Chen, providing short-term bridge financing. The Note carries a 0% interest rate and is intended to supply working capital for clinical development programs and general corporate operations.
The principal will automatically convert into Apollomics equity upon a future equity financing that raises at least $10,000,000, at a conversion price set at 80% of the lowest per-share price paid by new investors. If no such financing occurs before the 18‑month maturity, Mr. Chen may elect to convert based on the 10‑day average closing price. As a related-party transaction, it was reviewed by the independent Audit Committee and approved by the Board, with Mr. Chen abstaining.
Apollomics Inc. director and CEO Chen Hung-Wen reported his initial holdings. He holds 20,000 restricted stock units, each representing one Class A Ordinary Share. The RSUs vested for 5,000 shares on February 9, 2026, with 5,000 more vesting on each of March 15, 2026, June 15, 2026 and September 15, 2026. He also directly holds 133,334 Class A Ordinary Shares and indirectly 763,028 shares through King Regent Management Limited, over which he has voting and dispositive power while disclaiming beneficial ownership beyond his pecuniary interest.
Apollomics Inc. director Hong-Jung Chen filed an initial ownership report detailing equity and derivative holdings in the company. Chen directly holds 2,120 Class A Ordinary Shares. In addition, Chen has restricted stock units representing 2,000 Class A Ordinary Shares, with 500 units vested on February 9, 2026 and 500 more vesting on each of March 15, June 15 and September 15, 2026, subject to continued service.
Chen also holds stock options over 2,290 Class A Ordinary Shares at an exercise price of $75.00 per share, which are fully vested following a 1-for-100 reverse stock split adjustment. A second option grant covers 2,028 Class A Ordinary Shares at an exercise price of $6.20 per share and will vest in full on March 31, 2026, subject to continued service. The filing further discloses warrants linked to 304 Class A Ordinary Shares, reflecting an adjusted exercise price of $1,150.00 per full share, as each warrant is exercisable for 0.01 Class A Ordinary Share at $11.50 per warrant.
Apollomics Inc. director Huang Ya-Chi filed an initial ownership report showing a holding of restricted stock units tied to the company’s Class A Ordinary Shares. The filing reflects 2,000 restricted stock units, vesting in four installments of 500 shares each during 2026. Each unit represents the right to receive one Class A Ordinary Share.
Apollomics Inc. director CHU YI-AN reported initial beneficial ownership consisting of restricted stock units linked to Class A Ordinary Shares. The filing shows 2,000 underlying shares associated with these restricted stock units. According to the vesting terms, 500 units vested on February 9, 2026, with additional 500-unit tranches vesting on March 15, 2026, June 15, 2026 and September 15, 2026. Each restricted stock unit represents a contingent right to receive one Class A Ordinary Share.
Apollomics Inc. director TSAI HSIEN-SHU reported an initial holding of restricted stock units that are linked to the company’s Class A Ordinary Shares. The position covers restricted stock units tied to 2,000 underlying Class A Ordinary Shares held directly.
According to the footnotes, these restricted stock units vested with respect to 500 shares upon grant on February 9, 2026, with an additional 500 shares scheduled to vest on each of March 15, 2026, June 15, 2026 and September 15, 2026. Each unit represents a contingent right to receive one Class A Ordinary Share.
Apollomics Inc. director Jan Chen-Huan reported initial beneficial ownership of 2,000 Restricted Stock Units (RSUs), each tied to one Class A Ordinary Share. The RSUs vested with respect to 500 shares on February 9, 2026, with additional 500-share tranches scheduled on March 15, 2026, June 15, 2026 and September 15, 2026. Each RSU represents a contingent right to receive one Class A Ordinary Share, and the position is held directly.
Apollomics Inc. director and COO Chen Yi-Kuei filed an initial Form 3 reporting his equity holdings. He directly holds restricted stock units covering 20,000 Class A Ordinary Shares, vesting in four installments of 5,000 shares each during 2026. Each unit represents the right to receive one share. Through Maxpro Investment Co., Ltd., he is attributed 101,248 Class A Ordinary Shares and warrants exercisable for 3,823 Class A Ordinary Shares at an adjusted exercise price of $1,150.00 per full share, or $11.50 per warrant. He disclaims beneficial ownership of the Maxpro-held securities except to the extent of his pecuniary interest.